FDA Approves Upadacitinib for Non-Radiographic Axial Spondyloarthritis in patients with objective signs of inflammation who have had an inadequate response or intolerance to tumor necrosis factor (TNF) blocker therapy. https://t.co/ieaYyznlec https://t.co/YafTOxh8Cr